CoLucid Pharmaceuticals Announces Relocation of Company Headquarters to Massachusetts

USA - English

• USA - English

BURLINGTON, Mass., March 24, 2015 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, Lasmiditan, for the acute treatment of migraine headaches, announced today the relocation of its corporate headquarters to Massachusetts. The Company is currently operating in Burlington while it searches for office space in the Cambridge area.

"We are very proud to have been a North Carolina-based company since our inception. However, given the expansion of our management team with Massachusetts-based executives, we feel it is the right time to relocate. Cambridge is the heart of the biotechnology industry and we are very excited to be a part of all the innovation and excitement that takes place here every day," said Thomas P. Mathers, Chief Executive Officer of CoLucid.  

"We are thrilled to welcome CoLucid Pharmaceuticals to the Massachusetts life sciences community," said Robert K. Coughlin, President and CEO of MassBio, the Massachusetts life sciences trade association. "We know CoLucid will thrive in the ecosystem of innovation and collaboration here in the Commonwealth as they work to advance treatments for CNS disorders."

ABOUT LASMIDITAN

Lasmiditan has been designed to deliver efficacy for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies.  It selectively targets 5-HT_1F receptors expressed in the trigeminal pathway.  Its novel chemical class and differentiated site and mechanism of action led to lasmiditan's designation as a "ditan," a new drug class, by the INN and USAN.

CoLucid has successfully completed seven clinical studies for Lasmiditan, including a TQTc study and a Phase 2b study treating a single migraine attack in 391 patients. Phase 3 development will address major unmet medical needs in patients who are poorly served by currently available therapies to include patients with risk factors for cardiovascular disease who may not be able to take triptans.

We have a Special Protocol Assessment agreement with the FDA for our first pivotal Phase 3 clinical trial, SAMURAI, which includes two endpoints for the approval of acute migraine therapies—a primary endpoint of the proportion of patients who are free of headache pain two hours after dosing and a key secondary endpoint of the proportion of patients who no longer suffer from their most bothersome associated symptom of migraine (nausea, photophobia, phonophobia) two hours after dosing.

ABOUT MIGRAINE

Migraine is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation.  An estimated 36 million Americans suffer from migraine.  Migraine can be extremely disabling and costly, accounting for more than an estimated $20 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States.

ABOUT COLUCID PHARMACEUTICALS, INC.

CoLucid was founded in 2005 and is developing oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathlon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds.

CoLucid has entered into a distribution and supply agreement with ILDONG Pharmaceutical Co, Ltd. for Lasmiditan covering South Korea and certain Southeast Asia countries.

For more information please visit www.colucid.com.

Logo - http://photos.prnewswire.com/prnh/20130626/LA37332LOGO

SOURCE CoLucid Pharmaceuticals, Inc

Related Links

http://www.colucid.com